MedPath

Intervention With n-3 Polyunsaturated Fatty Acids (PUFA)-Supplemented Products in Moderate Hypertriglyceridemic Patients

Not Applicable
Completed
Conditions
Hypertriglyceridemia
Interventions
Dietary Supplement: n-3 PUFA
Registration Number
NCT01437930
Lead Sponsor
University of Jena
Brief Summary

The study was performed to investigate the effects of a daily consumption of n-3 PUFA supplemented products (sausage, bread rolls, wafers, milk beverage) on cardiovascular risk factors in hypertriglyceridemic patients.

Detailed Description

Recent studies suggest that n-3 LC-PUFA intake might be useful to prevent coronary heart diseases.

As a precondition for participating in this study, the patients were provided information in writing and verbally about the details of the study. Written informed consent was obtained from all volunteers. Before the beginning of the study, all participants were subject to a medical examination by their general practitioners. Sixty hypertriglyceridemic patients (with triacylglyceride (TAG) values ≥ 150 mg/dl or ≥ 1.7 mmol/L) should entered the study.

The placebo-controlled, randomized double-blind cross-over study consists of two investigation periods of 10 weeks, with a ten-week washout period in between. After the washout period the intervention was crossed between the groups and the respective products were consumed for another 10 weeks. Patients in the placebo period receive 60g sausage, 2 bread rolls (2x50g), 2 wafers and one bottle of the milk beverage daily. These products were enriched with sunflower oil (20g/d).

In the intervention period, the products (60g sausage, 2 bread rolls (2x50g), 2 wafers and one bottle of the milk beverage) were enriched with a) 20g linseed oil, b) 20g echium oil, and c)12g microalgae powder. The daily dose of special n-3 fatty acid amounted to a) 10g alpha linolenic acid (ALA), b 2g stearidonic acid (SDA)+6g ALA, or c) 2g docosahexaenoic acid (DHA).

Venous blood is collected at the beginning and at the end of each period.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
60
Inclusion Criteria
  • TAG values ≥ 150 mg/dl or ≥ 1.7 mmol/L
Exclusion Criteria
  • Lipid lowering medications
  • Glucocorticoids
  • Gastrointestinal or metabolic diseases (e.g., diabetes mellitus, hyperthyroidism or hypothyroidism, hypercholesteremic patients with familial previous impacts)
  • Daily alcohol abuse
  • Taking dietary supplements (e. g., fish oil capsules, vitamin E)
  • Known allergies or foodstuff indigestibility

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
placebon-3 PUFAproducts (sausage, bread rolls, milk beverage, wafers) enriched with 20g sunflower oil/d
Primary Outcome Measures
NameTimeMethod
blood lipids (total cholesterol, high density lipoprotein (HDL), low density lipoprotein (LDL), TAG)10 weeks
Secondary Outcome Measures
NameTimeMethod
vascular cell adhesion molecule10 weeks

vascular cell adhesion molecule

lipoprotein a10 weeks

Lipoprotein(a)

blood pressure10 weeks
high sensitive C-reactive protein10 weeks
oxidised LDL10 weeks
intracellular adhesion molecule10 weeks

intracellular cell adhesion molecule

fatty acid distribution in plasma lipids and erythrocyte membranes10 weeks

Trial Locations

Locations (1)

Friedrich Schiller University, Institute of Nutrition

🇩🇪

Jena, Germany

© Copyright 2025. All Rights Reserved by MedPath